findmyKOL
Clinical trialNCT05766748UnknownPhase 1/PHASE2Interventional

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

SponsorCantex PharmaceuticalsEnrollment30Metastatic Pancreatic Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California, United States

    Recruiting
  • Boca Raton Regional Hospital, Lynn Cancer Institute

    Boca Raton, Florida, United States

    Recruiting
  • Williamette Valley Cancer Institute and Research Center

    Eugene, Oregon, United States

    Recruiting
  • Ahn Cancer Institute - Allegheny General Hospital

    Pittsburgh, Pennsylvania, United States

    Recruiting
  • Prisma Health - Upstate

    Greenville, South Carolina, United States

    Recruiting
  • Texas Oncology - Northeast Texas

    Tyler, Texas, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

3-(4-(2-Butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethyl-1-propanamine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Jun 2023
Primary completion
28 Feb 2025
Completion
31 May 2025
Last update posted
14 Jun 2024
Registered enrollment
30
Registry id
NCT05766748
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.